BioSpace News Archive

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today the Company’s Board of Directors has authorized a 7.6% increase in its quarterly dividend from $0.66 to $0.71 per share.

FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Thursday, February 16 at 3:40 PM Eastern Time.

Revolution Medicines, Inc. today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be the featured speaker in fireside chats at the Guggenheim Healthcare Talks 2023 Oncology Conference.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2022.

Tango Therapeutics , Inc. today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in February.

Theralase® Technologies Inc. announced today that its Phase II Bacillus Calmette Guerin (“ BCG ”) Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”) clinical study (“Study II”) (Interim) data has been accepted by the American Urology Association (“AUA”) for a moderated poster presentation at its annual meeting.

ProSciento, Inc., a leading specialty clinical research organization (CRO) exclusively focused on metabolic diseases, today announced the appointment of David Sockolof to the role of Chief Financial Officer (CFO).

CTI BioPharma Corp. (Nasdaq: CTIC) today announced that senior leadership will participate in a Fireside Chat at the following investor conferences in February 2023.

JMIR AI is focused on the intersection between clinical neuroscience and technology to prevent, diagnose, and treat neurological disorders.

Repare Therapeutics Inc. today announced that members of its senior management team will participate at two investor conferences in February and March.